NorthSea Therapeutics now has three phase II clinical stage assets in development based  on its SEFA platform   Top line results of Phase 2b ICONA trial with lead programme icosabutate for NASH  expected in Q1 2023   Phase 1 trial with SEFA-1024 (being developed for the treatment of severe  hypertriglyceridemia) completed in Q4 2022 and is expected to … Continue reading NorthSea Therapeutics provides clinical update reflecting progress across NASH and metabolic disorders programmes